Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 12/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 11/20 | 0.58 |
| ▸ | RAB9A | P51151 | 10/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 10/20 | 0.58 |
| ▸ | HPGD | P15428 | 10/20 | 0.58 |
| ▸ | CASP3 | P42574 | 3/20 | 0.58 |
| ▸ | SENP8 | Q96LD8 | 3/20 | 0.58 |
| ▸ | SENP7 | Q9BQF6 | 3/20 | 0.58 |
| ▸ | SENP6 | Q9GZR1 | 3/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 11/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 7/20 | 0.57 |
| ▸ | TP53 | P04637 | 6/20 | 0.57 |
| ▸ | MMP2 | P08253 | 1/20 | 0.47 |
| ▸ | MMP9 | P14780 | 1/20 | 0.47 |
| ▸ | MMP8 | P22894 | 1/20 | 0.47 |
| ▸ | MMP13 | P45452 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9603983 | 0.91 | KDM4E (0.55) | NPC1KDM4ERAB9ASMN1; SMN2HPGD | |
| SCHEMBL9604010 | 0.88 | NPC1 (0.54) | NPC1KDM4ERAB9ASMN1; SMN2HPGD | |
| SCHEMBL9603982 | 0.87 | NPC1 (0.50) | NPC1KDM4ERAB9ASMN1; SMN2HPGD | |
| SCHEMBL9604012 | 0.85 | NPC1 (0.48) | NPC1KDM4ERAB9ASMN1; SMN2HPGD | |
| SCHEMBL9604014 | 0.83 | KDM4E (0.61) | NPC1KDM4ERAB9ASMN1; SMN2HPGD | |
| SCHEMBL9603992 | 0.82 | NPC1 (0.49) | NPC1KDM4ERAB9ASMN1; SMN2HPGD | |
| SCHEMBL9604003 | 0.82 | NPC1 (0.49) | NPC1KDM4ERAB9ASMN1; SMN2HPGD | |
| SCHEMBL8281383 | 0.81 | NPC1 (0.55) | NPC1KDM4ERAB9ASMN1; SMN2HPGD | |
| SCHEMBL9604004 | 0.81 | NPC1 (0.48) | NPC1KDM4ERAB9ASMN1; SMN2HPGD | |
| SCHEMBL8281468 | 0.81 | NPC1 (0.45) | NPC1KDM4ERAB9ASMN1; SMN2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8546584-B2 | Benzoxazole derivative, light-emitting element, light-emitting device, electronic device, and lighting device | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2013-10-01 | — | — | US | disclosed |
| US-8546584-B2 | Benzoxazole derivative, light-emitting element, light-emitting device, electronic device, and lighting device | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2013-10-01 | — | — | US | disclosed |
| US-20120132896-A1 | Benzoxazole Derivative, Light-Emitting Element, Light-Emitting Device, Electronic Device, and Lighting Device | SEMICONDUCTOR ENERGY LABORATORY CO., LTD | 2012-05-31 | — | — | US | disclosed |
| US-20120132896-A1 | Benzoxazole Derivative, Light-Emitting Element, Light-Emitting Device, Electronic Device, and Lighting Device | SEMICONDUCTOR ENERGY LABORATORY CO., LTD | 2012-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120132896-A1 | Benzoxazole Derivative, Light-Emitting Element, Light-Emitting Device, Electronic Device, and Lighting Device | XDH, AOX1, CYP4X1 | NPC1 4611/4885KDM4E 2142/4885RAB9A 3002/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.